

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Mediwelcome Healthcare Management & Technology Inc.**

**麥迪衛康健康醫療管理科技股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 2159)**

### **VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE**

This announcement is made by Mediwelcome Healthcare Management & Technology Inc. (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company hereby announces that it intends to, subject to market conditions, repurchase shares of the Company (the “**Shares**”) in the open market in accordance with the general mandate (the “**Repurchase Mandate**”) granted by the shareholders of the Company (the “**Shareholder(s)**”) to the Board pursuant to the resolution of the Shareholders passed at the annual general meeting of the Company held on 24 June 2022 (the “**AGM**”). Pursuant to the Repurchase Mandate, the Board is allowed to exercise the power of the Company to repurchase up to 10% of the aggregate number of Shares in issue as at the date of the AGM, i.e., up to 20,000,000 Shares. The Company will conduct the repurchase of Shares in compliance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), the Codes on Takeovers and Mergers and Share Buy-backs (the “**Takeovers Code**”), the Companies Act of the Cayman Islands and all other applicable laws and regulations.

The Board considers that the current Share price is below its intrinsic actual value and the Board considers that the repurchase of Shares will demonstrate the Company’s confidence in its business outlook and prospects and would ultimately benefit the Company and create value to the Shareholders. Therefore, the Board considers that repurchase of Shares is in the best interest of the Company and its Shareholders as a whole. The Board believes that the current financial resources of the Company would enable it to implement the repurchase of Shares while maintaining a solid financial position.

The Directors have no intention to exercise the Repurchase Mandate to the extent that would result in the number of Shares in the hands of the public falling below the prescribed minimum percentage as required by the Stock Exchange or give rise to an obligation to make a general offer to the Shareholders under Rules 26 and 32 of the Takeovers Code.

**Shareholders and potential investors of the Company should note that the exercise of the Repurchase Mandate by the Company will be subject to market conditions and will be at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase or whether the Company will make any repurchases at all. Shareholders and potential investors of the Company should therefore exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Mediwelcome Healthcare Management & Technology Inc.**  
**Shi Wei**  
*Chairman and Executive Director*

Hong Kong, 5 December 2022

*As at the date of this announcement, the executive Directors are Mr. Shi Wei, Mr. Yang Weimin, Mr. Wang Liang, Mr. Wang Wei and Mr. Sui Huijun; the non-executive Directors are Ms. Zhang Yitao and Mr. Liu Xia; and the independent non-executive Directors are Mr. Song Ruilin, Mr. Fei John Xiang, Mr. David Zheng Wang and Mr. Yang Xiaoxi.*